OpenEvidence reached a $12 billion valuation as investor demand climbed behind its clinician‑first AI medical search tool, which the company says is used regularly by more than 430,000 clinicians. The startup combines free clinician access with targeted pharmaceutical advertising and reported a revenue run rate above $100 million. The funding and business model signal expanding commercial pathways for AI tools that serve prescribers directly. Pharma companies may accelerate partnerships and targeted education via these platforms, but commercial success will depend on regulatory constraints for medical advertising, data governance, and clinician trust.